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The prosurvival and proapoptotic proteins of the
BCL-2 family share a similar three-dimensional fold
despite their opposing functions. However, many
biochemical studies highlight the requirement for
conformational changes for the functioning of both
types of proteins, although structural data to support
such changes remain elusive. Here, we describe the
X-ray structure of dimeric BCL-W that reveals amajor
conformational change involving helices a3 and a4
hinging away from the core of the protein. Biochem-
ical and functional studies reveal that the a4-a5 hinge
region is required for dimerization of BCL-W, and
functioning of both pro- and antiapoptotic BCL-2
proteins. Hence, this structure reveals a conforma-
tional flexibility not seen in previous BCL-2 protein
structures and provides insights into how these regu-
lators of apoptosis can change conformation to exert
their function.
INTRODUCTION
Interactions between the prosurvival and proapoptotic factions
of the BCL-2 family of proteins regulate the intrinsic apoptosis
pathway. Apoptosis ensues when the essential mediators of
apoptosis, BAX, and BAK, adopt an ‘‘activated’’ conformation,
allowing them to oligomerize on the mitochondrial outer mem-
brane (Youle and Strasser, 2008). These oligomeric complexes
form putative pore-like structures allowing for the release of
cytochrome c and other apoptogenic factors from the mitochon-
dria into the cytosol, resulting in the activation of the cellular
demolitionists, the caspases. No structures have yet been re-
ported for activated BAX or BAK, although biochemical and
biophysical studies provide insights into the conformational
changes that occur following their activation. These conforma-
tional changes include exposure of the N-terminal a1 helix (Gop-
ing et al., 1998; Griffiths et al., 2001; Hsu and Youle, 1997), and of
the a2 helix (Czabotar et al., 2011; Dewson et al., 2008; Ku et al.,Structure 19, 1467–12010) as required for insertion of the BAX/BAK BH3 domain into
the binding groove of a partner molecule when homodimers or
heterodimers form.
Recent crosslinking studies provide compelling evidence for
the formation of dimers of BAK prior to assembly of the higher
order oligomeric complex (Dewson et al., 2008, 2009). In this
model, dimers form by reciprocal binding of the BH3 domain
on helix a2 of one BAK molecule into the canonical BH3-binding
groove on a partner BAK molecule (Dewson et al., 2008). Higher
order oligomers may then form through interactions involving
helix a6 (Dewson et al., 2009). Two BAK crystal structures reveal
different potential modes of dimer formation (Moldoveanu et al.,
2006;Wang et al., 2009), although neither of these represents the
dimer in the model proposed above (Dewson et al., 2009).
A number of different modes of dimerization of the prosurvival
BCL-2 proteins have also been described. Evidence for a ‘‘tail-
swapped dimer’’ of BCL-XL in cells has been reported (Jeong
et al., 2004), whereas different and extensive binding interfaces
are involved in BCL-2 homodimerization (Zhang et al., 2004).
Structures of alkali- or heat-treated BCL-XL reveal a dimeric
structure that forms due to a three-dimensional domain swap
involving helices a6–a8 (Denisov et al., 2007; O’Neill et al.,
2006; Pagliari et al., 2005). Structures revealing domain swaps
involving the a1 helix have also been reported in dimers of an
engineered form of BCL-XL (Oberstein et al., 2007), and the viral
BCL-2 homolog, F1L (Kvansakul et al., 2008). Although, the
physiological relevance of such structures is unclear, they pro-
vide insights into the dynamic properties of the BCL-2 family
fold, and the stability of subdomains within it. Paradoxically,
the prosurvival BCL-2 proteins possess similar three-dimen-
sional structures to the inactive forms of BAX and BAK. Although
numerous reports have shown that at least some prosurvival
proteins (i.e., BCL-XL and BCL-2) possess ion-channel activity
in artificial membranes (Minn et al., 1997; Schendel et al.,
1997), there is a smaller body of work supporting their abilities
to form pores similar to that of BAX and BAK (Basan˜ez et al.,
2001). Why BAX and BAK are different in this regard is still
unknown, but may relate to their ability to form higher order
oligomers.
In addition to the conformational changes associated with
BAX and BAK activation and oligomerization, a body of evidence476, October 12, 2011 ª2011 Elsevier Ltd All rights reserved 1467
Figure 1. BCL-W DC but Not BCL-2 DC Forms a Dimer
(A) Preparative gel filtration chromatography of BCL-W and BCL-2 on a Superdex 75 16/60 column. BCL-W elutes as two peaks (labeled 1 and 2). Peak 1 elutes at
a volume consistent with a dimer (40 kDa) whereas Peak 2 has an elution volume consistent with a monomer. The ratio of dimer/monomer varies between
preparations ranging from 5:1 as shown, to 1:1. BCL-2 always elutes as a monomer when purified in the same manner.
(B) Sedimentation velocity analysis using an analytical ultracentrifuge confirms that Peak 1 and Peak 2 represent dimeric and monomeric forms of BCL-W
respectively.
(C) The stability of the BCL-W dimer was analyzed by gel-filtration chromatography (Superdex 75 10/300 column) following storage at either 4C or room
temperature (RT) for the indicated times.
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Crystal Structure of a BCL-W Dimersuggests that the membrane-embedded form of BCL-2
family proteins has a different three-dimensional structure to
that seen in solution, and in crystals. This hypothesis
arises because the helical hairpin a5-a6, that some reports
have shown is required for membrane insertion of BAX and
BCL-2 (Annis et al., 2005; Dlugosz et al., 2006), is buried in the
core of BCL-2 family proteins. Dewson and Kluck (2009) have
speculated that the conformational changes required to expose
helices a5-a6 could also disrupt the BH3 binding groove that is
required for their model of BAK/BAX oligomerization, and
propose that alternative models of membrane insertion warrant
consideration.
Here we report that another BCL-2 prosurvival family
member BCL-W, forms domain-swapped dimers. These dimers
are not induced by a physico-chemical stimulus but rather are
a property of the amino acid sequence of BCL-W. A conse-
quence of the associated conformational changes is the expo-
sure of helices a5 and a6, although the BH3 binding groove
remains intact, albeit in a different structural context, and
retains the ability to bind BH3 domain sequences. Moreover,
a ‘‘hinge’’ sequence necessary for BCL-W dimerization was
found to be important for both BCL-W functioning and for the
proapoptotic activity of BAK. Hence, this structure provides
further evidence of the conformational flexibility inherent in
the BCL-2 fold and new insights into the functioning of these
proteins.1468 Structure 19, 1467–1476, October 12, 2011 ª2011 Elsevier LtdRESULTS
BCL-W DC29 Forms Dimers
Although previous NMR structural studies of BCL-W have shown
the protein to be monomeric in solution (Denisov et al., 2003;
Hinds et al., 2003), we have found that a significant proportion
(ranging from 50% to 80% in different preparations) of
BCL-W without its membrane anchor (DC29) purified from
Escherichia coli extracts, was dimeric as assessed by gel-filtra-
tion chromatography and analytical ultracentrifugation (Figures
1A and 1B). An equivalent construct of BCL-2 (DC22) expressed
and purified identically was consistently entirely monomeric in
our preparations, as assessed by gel-filtration chromatography
(Figure 1A). The BCL-W dimer forms without any inducement
as reported for some BCL-XL dimers (Denisov et al., 2007;
O’Neill et al., 2006), and is stable at 4C although it equilibrates
over several days with the monomer if stored at room tempera-
ture (Figure 1C).
The BCL-W Dimer Structure Reveals a Novel
Domain-Swapped Conformation
To determine whether the dimer formed by BCL-W is similar to
any previously reported dimeric BCL-2 family proteins, we deter-
mined its structure by X-ray crystallography (see Table 1 for
crystallographic statistics; Protein Data Bank [PDB] ID: 2Y6W).
The structure reveals a novel domain-swapped conformationAll rights reserved
Table 1. Crystallographic Statistics for BCL-W Dimer
Data collection
Space group P43212
Unit cell a = 76.2 A˚, c = 112.8 A˚
Resolution range 49 A˚ –2.0 A˚
Reflections 23,159
Multiplicity 11.8 (11.8)
Completeness (%) 99.9 (99.5)
I/s(I) 20.5 (2.2)
Rmerge 0.085 (1.31)
Refinement
Resolution range 49–2.0 (2.09–2.00) A˚
Reflections (work/test) 21,982/1157
Protein atoms 2270
Solvent atoms 199
Rwork 0.199 (0.242)
Rfree 0.244 (0.277)
Rmsd bonds 0.008 A˚
Rmsd angles 1.05
Numbers in parenthesis refer to highest resolution shell. rmsd, root-
mean-square deviation.
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Crystal Structure of a BCL-W Dimerinvolving helicesa3anda4 (Figure 2A) hinging away from the core
of the protein and crossing into another BCL-W protomer. The
hinge points for the structural rearrangement are located in the
segments linking helices a2 to a3 and a4 to a5. As a conse-
quence, a2 and a3, which subtend an angle of90 to each other
in the monomer structure, are now more nearly collinear (240)
(Figure 2B). In prosurvival proteins, helices a3 and a4 form one
end of the BH3 ligand-binding groove (Petros et al., 2004).
Althoughdimerization ofBCL-Woccurs as a result of a conforma-
tional change involving these helices, the binding groove remainsStructure 19, 1467–1largely intact. However, it now overlays helices a5 and a6 from
the partner polypeptide in the dimer, and its orientation relative
to a5-a6 is somewhat different to that seen in the monomeric
BCL-W structure (Denisov et al., 2003; Hinds et al., 2003) (Fig-
ure 2C). The BH3-binding groove of the partnermolecule clashes
with that of the first, suggesting that only one BH3 peptide can
bind the BCL-W dimer (see Figure S1 available online).
Some BH3 Peptides Can Bind the BCL-W Dimer
and Induce High-Order Oligomerization
Due to the different orientation of the BH3 binding groove in the
BCL-W dimer relative to the monomer, we examined whether
both forms could engage BH3 ligands similarly. Isothermal titra-
tionmicrocalorimetryanalysisof the interactionwithapeptidecor-
responding to theBH3domain ofBAD, confirmed that the peptide
binds the dimer, although the affinity measured (KD: 150 nM) was
10-fold weaker than for monomeric BCL-W (KD: 14 nM) (Fig-
ure 3A). Interestingly, the stoichiometryof the interaction indicated
that the dimer can only bind one peptide ligand (ligand/BCL-W
dimer 0.5:1 compared with monomeric BCL-W 1:1). Negligible
binding of the dimer with a NOXA BH3 peptide was observed,
as with monomeric BCL-W (Figure 3B) (Chen et al., 2005), sug-
gesting that the selectivity profile of the protein was unchanged.
We also assessed whether treatment of the BCL-W dimer with
BH3 peptides induced a change to its oligomeric state. Most
BH3 peptides had little or no effect. However, BIM and PUMA
peptides induced conversion to a higher order oligomer (Fig-
ure 3C), which we confirmed was a tetramer by analytical ultra-
centrifugation (Figure 3D).
The a4-a5 Linker Region Affects Functioning of BCL-W
One of the hinge points for the conformational change seen in
the BCL-W dimer is the segment linking helices a4 and a5.
The amino acid sequence of this linker in BCL-W differs from
that in BCL-XL and BCL-2 (QGGPNWGRL in BCL-W andFigure 2. Crystal Structure of BCL-W DC Dimmer
(A) The BCL-W dimer (protomers in green and blue)
involves a domain swap of helices a3 and a4.
(B) Overlay of one protomer from the dimer (blue) with the
NMR structure of the BCL-Wmonomer (PDB: 10OL) (pink).
The structures are essentially identical except for helices
a3 and a4.
(C) Overlay of the ‘‘binding groove’’ from one protomer of
the BCL-W dimer (red) with the NMR structure of BCL-W
monomer (pink with ‘‘groove’’ in yellow) reveals a some-
what different orientation relative to the protein core.
(D) The BCL-W dimer has a 10 A˚ pore-shaped tunnel co-
incident with the dimer dyad axis.
See also Figure S1.
476, October 12, 2011 ª2011 Elsevier Ltd All rights reserved 1469
Figure 3. BH3 Peptides from BIM, and to a Lesser Extent PUMA, Converts BCL-W DC Dimer to a Tetramer
(A) ITC analysis of BCL-W dimer and BCL-W monomer binding to a synthetic peptide corresponding to the BAD BH3 domain. The stoichiometry for the dimer/
peptide interaction is 0.5:1 whereas for the monomer/peptide interaction is 1:1.
(B) Negligible binding to a NOXA BH3 peptide is observed for both the dimer and monomer as analyzed by ITC.
(C) The effect of treatment of BCL-W dimer with various BH3 peptides was assessed by gel-filtration chromatography. The protein was incubated with each
peptide at a 2-fold molar excess for 1 hr at room temperature prior to injection on a gel-filtration column (Superdex 75 10/300). Only BIM, and to a lesser extent
PUMA, have an effect on the oligomeric state of the protein, converting it to a tetramer as assessed by analytical ultracentrifugation.
(D) Sedimentation velocity analysis using an analytical ultracentrifuge confirms that the higher molecular weight form of BCL-W that is generated following
incubation with BIM BH3 peptide is a tetramer. BCL-W monomer and dimer samples were included as controls.
Structure
Crystal Structure of a BCL-W DimerRDGVNWGRI in BCL-2/BCL-XL). To determine whether this
sequence difference could influence the protein conformation,
we switched the underlined residues in BCL-W DC29 for the
corresponding residues in BCL-2/BCL-XL. When expressed
and purified identically to wild-type BCL-W DC29, the protein
was predominantly monomeric (Figure 4A), indicating that the
linker sequence is a determinant of protein conformation.
We next investigated the biological role of the a4-a5 hinge
in full-length BCL-W in cells. Mouse embryonic fibroblasts
(MEFs) were more resistant to either ABT-737 (a BCL-W antag-
onist) or to etoposide when wild-type BCL-W was overex-
pressed (Figures 4B and 4C). However, the BCL-W chimera
(BCL-W mt) with the a4-a5 linker sequence replaced with the
corresponding sequence in BCL-2 (and BCL-XL) (Figure 4A)
showed enhanced protection against both stimuli (Figures 4B
and 4C). We also examined the ability of both wild-type
BCL-W and the BCL-W mt to protect against cytochrome c
release, a hallmark of apoptosis signaling following exposure1470 Structure 19, 1467–1476, October 12, 2011 ª2011 Elsevier Ltdto a death stimulus. Consistent with the killing data, relatively
less cytochrome c release induced by a BIM BH3 peptide was
observed from permeabilized MEFs expressing BCL-W mt
compared toMEFs expressing wild-type BCL-W. This enhanced
protection of the BCL-W mt against different death stimuli
occurs despite its significantly lower expression levels com-
pared to wild-type BCL-W (Figure 4E). Although the mechanism
of protection in these assays is likely complex, the data demon-
strate that the a4-a5 linker sequence influences BCL-W function.
Moreover, the combined data from the biochemical and func-
tional studies suggest that BCL-W anti-apoptotic function is
enhanced by replacement of its a4-a5 hinge sequence with
one that restrains its conformational flexibility.
The a4-a5 Linker Region Affects Functioning
of Proapoptotic BAK
Given the structural and sequence homology of the prosurvival
and proapoptotic multidomain BCL-2 proteins, we examinedAll rights reserved
Figure 4. Functional Role of the a4-a5 Hinge in BCL-W
(A) Preparative gel-filtration chromatography of BCL-W DCmutant (BCL-Wmt) in which the a4-a5 hinge residues were replaced with the corresponding residues
from BCL-2. This protein is consistently purified predominantly as a monomer.
(B and C) Overexpression of full-length BCL-W rescues (B) mcl-1/MEFs from killing by ABT-737 and (C) wild-type MEFs by etoposide, although the mutated
a4-a5 linker BCL-W construct is more potent.
(D) Relatively less cytochrome c is released from the pellet fraction (P) containing mitochondria into the soluble fraction (S) in cells expressing the BCL-W hinge
mutant compared to cells expressing wild-type BCL-W following treatment with BIM. (D) The increased potency of the BCL-W mutant occurs even though it is
less well expressed than wild-type BCL-W. Data in (B) and (D) represent means ± SD (error bars) of three experiments.
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Crystal Structure of a BCL-W Dimerhow the linker a4-a5 sequence could influence functioning of
proapoptotic proteins. We reconstituted bax/bak/ MEFs
with wild-type BAK or chimeric BAK in which the a4-a5 hinge
sequence (ESGINWGRV) was replaced either with the BCL-W
(BAK/Whinge) or BCL-2 (BAK/2hinge) linker. Depending on the
sequence inserted, we observed different functional outcomes
following exposure of these cells to various apoptotic stimuli.
BAK/2hinge-expressing cells were killed as effectively as those
expressing wild-type BAK following exposure to UV irradiation
(Figure 5A), treatment with etoposide (Figure 5B), or overexpres-
sion of BIM (Figure 5C). In contrast, essentially no effect on the
viability of cells expressing the BAK/Whinge protein was
observed (Figures 5A–5C). Similar levels of expression for both
chimeras were observed in these cells (Figures 5D).
To investigate the underlying basis for the functional differ-
ences between the BAK chimeras, we first examined the cellular
localization of each protein. Both proteins localized to the
membrane fraction following digitonin permeabilization, similar
to wild-type BAK (Figure 5E). Oligomerization of BAK is essential
for its apoptotic function. To analyze the ability of the BAK
mutants to oligomerize, membrane fractions were treated with
the activator of BAK, recombinant tBID, and BAK was examined
on Blue Native polyacrylamide gels (BN-PAGE). The majority of
wild-type BAK and of BAK/2hinge converted from a monomer
(which is the predominant form in untreated cells) to a dimer (Fig-Structure 19, 1467–1ure 5F). This conversion was significantly less efficient for BAK/
Whinge where the majority of the protein remained monomeric.
This suggests that BAK/Whinge fails to kill cells as it does not
homo-oligomerize in response to an apoptotic stimulus.
BAK oligomerization is a multistep process in which a key step
is the exposure of its BH3 domain that can bemonitored with the
4B5 antibody (Dewson et al., 2009). Once exposed, this BH3
epitope is then reburied or shielded following oligomerization
as it inserts into the binding groove in a partner BAK molecule.
Hence, the BH3 domain is occluded in both nonactivated and
oligomerized forms of BAK, and only when membrane fractions
are exposed to tBID in the presence of 4B5, can activated BAK
(i.e., BH3 domain exposed) be immunoprecipitated. Consistent
with this, wild-type BAK could be immunoprecipitated when
the 4B5 antibody was added during tBID treatment, but not
either before or after treatment with tBID (Figure 5C). BAK/2hinge
behaved exactly like wild-type BAK in these assays (Figure 5G).
In contrast, BAK/Whinge exposed its BH3 domain following tBID
treatment, but it remained largely exposed, clearly demon-
strating a failure to oligomerize via a BH3-in-groove interaction
with another BAK molecule. These data indicate that although
BAK/Whinge undergoes a conformation change in response to
an apoptotic stimulus, the substitution of the BCL-W hinge
precludes BH3:groove dimerization, consistent with the failure
of this protein to mediate cell death.476, October 12, 2011 ª2011 Elsevier Ltd All rights reserved 1471
Figure 5. Functional Role of the a4-a5 Hinge in BAK
(A–C) Overexpression of BAK or BAK in which the a4-a5 hinge sequence is replaced with that from BCL-2 (BAK/2hinge) in bax/bak/ MEFs makes them
sensitive to (A) ultraviolet irradiation, (B) treatment with etoposide, or (C) overexpression of BIM, but replacement of the corresponding BCL-W hinge sequence
(BAK/Whinge) renders it inactive.
(D) Relative expression levels of HA tagged BAK and BAK hinge mutants in bax/bak/ MEFs as determined by western blot.
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Structure
Crystal Structure of a BCL-W DimerAlthough BAK/Whinge can undergo the first step toward acti-
vation (i.e., BH3 exposure) it fails to oligomerize to allow full acti-
vation, hence we examined whether it could possibly act as a
dominant-negative mutant. Accordingly, we generated bax/
MEFs that overexpress either wild-type or both BAK hinge
chimeras, then treated each cell line with etoposide (Figures
5H and 5I). A dominant negative mutant would be expected to
inhibit the killing activity associated with the native BAK ex-
pressed in these cells whereas overexpression of a functional
BAK mutant might be expected to enhance killing activity due
to the increased levels of this protein in the cell. Unexpectedly,
in all cases we observed enhanced killing activity, even with
the BAK/Whinge chimera. Hence, although not capable of
inducing cell killing on its own, BAK/Whinge can enhance the
killing activity observed in cells expressing wild-type BAK.
DISCUSSION
Essentially all current models for how BCL-2 proteins regulate
and execute apoptosis requires the proteins to undergo sig-
nificant changes in their conformation from the form observed
in aqueous solution and in crystals. Such conformational alter-
ations are likely to be important for oligomerization, membrane
integration and/or pore assembly. However, although we can
use biochemical and other data to speculate about the nature
of such changes, there is still a dearth of actual structural data
to support or refute any particular model for how BCL-2 proteins
exert their function.
The BCL-W dimer structure reported here highlights the con-
formational flexibility and dynamic properties inherent in the
BCL-2 fold, and demonstrates a major structural change not
seen in any previous structures. Although it is possible to show
that BCL-W can form homodimers in cells (e.g., by immunopre-
cipitation; data not shown), it is much more difficult to establish
whether such dimers form in a manner similar to that seen in our
crystals. For example, homodimers of prosurvival proteins have
been shown to form by tail-in-groove interactions (such as in
BCL-XL) (Jeong et al., 2004), as well as binding through distinct
surfaces on the protein (as in BCL-2) (Zhang et al., 2004). As
such, we have focused our studies here on the physiological
relevance of the conformational flexibility seen in BCL-W rather
than the role of the dimer per se that might only form in the puri-
fied recombinant protein due to exposure of hydrophobic
surfaces on a5 and a6 following the unhinging of a3 and a4
from the core of the protein. Indeed, in the context of a cellular
milieu with membranes and numerous potential binding part-(E) The BAK/BCL-2 and BAK/BCL-W hinge mutants both localize to the memb
following digitonin permeabilization of bax/bak/ MEFs expressing these pro
(F) Treatment of the membranes isolated from digitonin-permeabilized MEFs with
mutant to a dimer whereas the BAK/Whinge mutant remains mostly monomeric,
(G) Addition of antibody 4B5 that binds the BAK BH3 domain together with tBID t
immunoprecipitation. However, addition of the antibody after treatment with tBID
mutant indicating that the 4B5 BH3 domain epitope was now shielded, whereas
7D10 antibody recognizes a distinct epitope to 4B5 and immunoprecipitated sim
after tBID treatment.
(H) Expression of wild-type or BAK hinge mutants in bax/ cells increases their s
from an empty vector.
(I) Relative expression levels of HA tagged BAK and BAK hinge mutants in bax/
SD (error bars) of three experiments.
Structure 19, 1467–1ners, as well as the presence of a C-terminal tail on BCL-W,
such dimers may not form, but the conformational flexibility is
an inherent property of the BCL-W structure.
Our biochemical data showed that the conformational flexi-
bility in BCL-W is sequence dependent; replacement of the
a4-a5 hinge with the corresponding sequence in BCL-2 pre-
vented dimer formation, most likely by restricting movement of
the a3-a4 helices. This BCL-W/2hinge chimera (BCL-W mt)
also displayed enhanced antiapoptotic activity in cells compared
to wild-type BCL-W. It is likely that BCL-W that is predominantly
monomeric (i.e., such as in the BCL-2 hinge-swap form) is more
able to engage BH3 sequences from proapoptotic proteins as
the binding groove is in the optimal conformation, explaining
this enhanced prosurvival activity. As the conformational change
we observe in BCL-W occurs spontaneously when the protein is
expressed in E. coli, this suggests that BCL-W possesses a
metastable structure that can switch between alternative confor-
mations. It is curious that the protein has evolved in such a way,
although perhaps this switching of conformers is a mechanism
by which its prosurvival function is restrained in cells. Notably,
despite BCL-W being able to engage multiple BH3 only proteins
and BAX/BAK with potencies comparable to its closest relatives
BCL-2 and BCL-XL, it is rarely implicated in tumorigenesis
(unlike BCL-2 and BCL-XL), and the phenotype associated
with its genetic ablation is significantly less dramatic than seen
following deletion of those other family members (Print et al.,
1998; Youle and Strasser, 2008). Accordingly, we can speculate
that excessive conformational flexibility in the BCL-W structure
limits its anti-apoptotic role in a physiological context.
Previous studies have shown that substitution of residues
within the corresponding hinge region of BCL-2 (that includes
the conserved BH1 domain) can impair its function (Yin et al.,
1994). For example, mutation of the glycine residue in the
‘‘NWGR’’ motif to alanine is detrimental, although this can be ex-
plained by numerous structural studies of BH3 domain/prosur-
vival protein complexes; that glycine is in a sterically restricted
region of the binding groove, and substitution for the larger
residue impedes binding of a BH3 domain within the groove.
Although not tested here, a similar outcome would also be ex-
pected for the same mutation in BCL-W. However, the detri-
mental effect of mutation of residues in BCL-2 within the a4-a5
loop preceding the NWGR motif (Yin et al., 1994) is not so easily
explained until now, without knowledge of the BCL-W dimer
structure, as these residues do not directly participate in interac-
tions with BH3 domains binding within the groove. However, by
reference to our structure, we can hypothesize that mutationsrane fraction (P) in cells, like wild-type BAK, as assessed by western blotting
teins. S, soluble fraction.
tBID results in conversion of the majority of wild-type BAK or the BAK/2hinge
as assessed by Blue Native PAGE.
o membranes from cells expressing either BAK or hinge mutants enables their
resulted in reduced immunoprecipitation of wild-type BAK and the BAK/2hinge
in the BAK/Whinge mutant, the BH3 domain remained exposed. The anti-BAK
ilar levels of BAK or BAK mutants regardless of whether it was added during or
ensitivity to etoposide compared to cells transduced with a retrovirus derived
MEFs as determined by western blot. Data in (A–C) and (H) represent means ±
476, October 12, 2011 ª2011 Elsevier Ltd All rights reserved 1473
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Crystal Structure of a BCL-W Dimerwithin this sequence could potentially impart undue flexibility to
the binding groove, and as a consequence, reduce its capacity
to engage other BH3 domains. The BCL-W dimer does retain
the ability to bind BH3 sequences although its affinity is reduced
ten-fold compared tomonomeric BCL-W and only one BH3 pep-
tide binds per dimer. The two canonical BH3-binding grooves on
the dimer clash with each other around the dyad axis as shown in
Figure S1, and modeling this interaction suggests that the
binding of even a single BH3 peptide is likely to require some
conformational change in the BCL-W dimer structure. To date
we have been unable to grow crystals of the BCL-Wdimer bound
to a BH3 peptide to explore this question further.
A model of metastability and conformation switching has
previously been invoked to explain how BAX might be able to
adopt an activated conformation in the absence of targeting by
a ‘‘direct activator’’ (Fletcher et al., 2008). Whether BAX/BAK
can undergo the same conformational changes seen here with
BCL-W remains to be determined, although our functional data
using BAK a4-a5 hinge chimeras suggest that this type of
conformational flexibility could be a liability for the functioning
of BAK as BAK/Whinge was inert due to its inefficient dimeriza-
tion. Hence, whereas the BCL-W hinge sequence promotes
BCL-W dimerization, it impairs (although not completely) BAK
homodimerization, suggesting two different modes of self-
association.
It is intriguing that the BAK/Whinge chimera could enhance the
killing observed in cells expressing wild-type BAK despite itself
being functionally inactive. One explanation for this result is
that themutant BAK, although unable to homo-oligomerize is still
capable of exposing its BH3 domain and auto-activating wild-
type BAK. Such auto activation has been suggested for BAX
where its BH3 domain becomes exposed following an initial
activation step, and then can engage other BAX molecules to
activate them in a ‘‘catalytic’’ manner (Gavathiotis et al., 2010).
Indeed we observe clear evidence for exposure of the BH3
domain from the BAK/Whinge chimera following a death-in-
ducing stimulus, although its BH3 domain also remains exposed
consistent with it not becoming engaged in a stable interaction
either with another BAK/Whinge molecule, or with the wild-
type BAK present in the cells. Hence, consistent with a previous
report (Ruffolo and Shore, 2003), our data supports a similar
autoactivation mechanism in BAK as that proposed for BAX.
Although BCL-W forms dimers in cells exposed to apoptotic
stimuli (Wilson-Annan et al., 2003), there is no evidence that
BCL-W can form pores in mitochondrial membranes (although
it is not unprecedented for prosurvival proteins to function in
this way [Basan˜ez et al., 2001]). However, an intriguing aspect
of this new structure is the presence of a ‘‘tunnel’’ coincident
with the dimer dyad axis, the interior walls of which are primarily
lined by helix a5 (Figure 2D). The narrowest opening of this
tunnel, formed by the linkers connecting a4 and a5, is 10 A˚ in
diameter. Biophysical analyses have shown that BAX (DC19)
dimerizes and forms small pores with an estimated size of 10 A˚
prior to assembly into the larger structure required for mitochon-
drial damage (Saito et al., 2000). Further experiments are needed
to establish the form of this BAX dimer, but this observation is
further evidence of the existence of a dimer intermediate
(although not necessarily like the BCL-W dimer described here)
in BAX activation.1474 Structure 19, 1467–1476, October 12, 2011 ª2011 Elsevier LtdOligomeric conformers of BCL-2 family proteins underlie
mitochondrial outer membrane permeabilization in apoptosis.
Although the dimeric BCL-W structure described herewith
does not conform to current models of how BAK in particular is
thought to form dimers and higher-order oligomers (Dewson
et al., 2008, 2009), it highlights the dynamic properties of
BCL-2 proteins and how this conformational flexibility can affect
function.
EXPERIMENTAL PROCEDURES
Expression and Purification of BCL-W
An N-terminal hexahistidine tagged human BCL-W DC29 (C29S, A128E)
construct was expressed in BL21 DE3 E. coli cells following induction with
IPTG for 3 hr at 37C. Cell pellets were resuspended in Tris-buffered saline
(TBS), pH 8, 10 mM 2-mercaptoethanol, and lysed by addition of lysozyme
(8 mg/g cell pellet) and deoxycholic acid (4 mg/g cell pellet) for 30 min
at room temperature. Following removal of cell debris by centrifugation,
BCL-Wwas purified from the supernatant by Ni-affinity chromatography using
a Hi-Trap chelating column charged with nickel chloride, followed by gel-filtra-
tion chromatography on a Superdex 75 16/60 column equilibrated and run in
TBS containing 10 mM 2-mercaptoethanol.
Crystallization and Structure Determination
Purified BCL-W dimer was concentrated to 10 mg/ml and crystals grown by
mixing 1:1 with 5% (w/v) PEG 3000, 40% (w/v) PEG 400, 0.1 M MES pH 6.5.
Prior to flash freezing in liquid nitrogen, crystals were equilibrated in 15%
ethylene glycol as cryoprotectant. X-ray diffraction data were collected at
the Swiss Light Source synchrotron and were integrated and scaled with
HKL2000 (Otwinowski and Minor, 1997). The structure was solved using
PHASER (McCoy et al., 2005; Read, 2001; Storoni et al., 2004) with murine
BCL-XL (PDB: 1PQ0) as the search model. Only one copy of the model was
located, although packing considerations suggested two per asymmetric
unit with 46% solvent. During early model building, a chain break at P91 per-
sisted and helix a3 seemed disconnected to the main structure. The domain-
swapped dimer described in the text emerged over multiple rounds of
model building in COOT (Emsley and Cowtan, 2004) and refinement in
REFMAC (Murshudov et al., 1997) and PHENIX (Adams et al., 2002). Strong
difference electron density located within the channel around the dimer axis
is adequately modeled as di- and tri-ethylene glycol. Thermal displacement
parameters for the segments G89, G90, P91 are high on both polypeptides.
Simulated annealing refinements with these segments omitted confirmed
that connectivity requires that the chain trace be as shown.
Isothermal Titration Microcalorimetry
Isothermal titration microcalorimetry (ITC) studies were performed using a
MicroCal VP-ITC instrument. Proteins were diluted to 10 mM in TBS and BH3
peptides (BAD: NLWAAQRYGRELRRMSDEFVDSFKKG; NOXA: PAELEVEC
ATQLRRFGDKLNFRQKLL) (prepared in the same buffer from 10 mM stocks),
were titrated from a 80 mM solution. All experiments were performed at 25C.
Data analysis was performed using the MicroCal Origin software.
Cell Killing Assays
Wild-type and mcl-1/ MEFs stably expressing wild-type BCL-W or the
BCL-W hinge mutant and bax/bak/ MEFs stably expressing wild-type
BAK or BAK hinge mutants were generated by retroviral transduction using
the pMIG vector in which expression of each construct is linked toGFP expres-
sion by an IRES sequence. Cells expressing GFP were sorted by flow cytom-
etry and used for cell killing assays. mcl-1/ cell lines expressing BCL-W
constructs were treated with serial dilutions of ABT-737 for 24 hr prior to
viability determination using the CellTiter-Glo luminescent assay (Promega).
Wild-type MEFs expressing BCL-W constructs or bax/bak/ cell lines
expressing BAK constructs were treated with etoposide for 24 hr, and/or
exposed to UV irradiation (150 J/m2) then viability assessed 24 hr later by
flow cytometric analysis of GFP+ve (FL-1) cells that excluded 5 mg/ml propi-
dium iodide (Sigma) (PIve; FL-3), using FACScan (Becton Dickinson). CellAll rights reserved
Structure
Crystal Structure of a BCL-W Dimerkilling by BIM was determined following infection of MEFs expressing wild-
type BAK or BAK hinge mutants with retroviruses expressing either wild-
type BIMS or an inert BIMSmutant (BIMS4E) in which the four conserved hydro-
phobic residues in the BH3 domain are replaced with glutamic acid. Infected
cells (expressing GFP) were sorted into 6-well plates and colonies counted
6 days later. Protein expression levels were determined by western blotting
using a rat anti-FLAG antibody (gift of Lorraine O’Reilly, WEHI).Analytical Ultracentrifugation
Sedimentation experiments were conducted in a Beckmanmodel XL-A analyt-
ical ultracentrifuge at a temperature of 20C. Samples dissolved in 20mMTris,
50 mM NaCl, pH 7.5 were loaded into a conventional double sector quartz cell
and mounted in a Beckman 4-hole An-60 Ti rotor. Sedimentation velocity
experiments, 380 ml of sample (0.7 mg/ml) and 400 ml of reference solution
were centrifuged at a rotor speed of 40,000 rpm. Data was collected (without
averaging) at a single wavelength (280 nm) in continuousmodewith a step-size
of 0.003 cm. Solvent density (1.00087 g/ml at 20C) and viscosity (1.0126 cp),
as well as estimates of the partial specific volume (0.7216 ml/g) and hydration
(0.398 g/g) of BCL-W were computed using the program SEDNTERP (Laue
et al., 1992). Sedimentation velocity data at multiple time points were fitted
to either a noninteracting discrete species model of up to three components
or a continuous size-distribution model (Perugini et al., 2000; Schuck, 2000;
Schuck et al., 2002; Vistica et al., 2004) using the program SEDFIT, which is
available at www.analyticalultracentrifugation.com.
Subcellular Fractionation
MEFs expressing the indicated BAK mutants were harvested and the cell
membrane was permeabilized by incubating with 0.025% digitonin in perme-
abilization buffer (20 mM HEPES/KOH pH 7.5, 100 mM sucrose, 2.5 mM
MgCl2, 50 mM KCl supplemented with Complete protease inhibitors [Roche,
Basel, Switzerland] and 2 mM DTT) on ice for 10 min. Cytosol and membrane
fractions were separated by centrifugation at 13,000 3 g for 5 min prior to
analysis by SDS-PAGE.
BAK Oligomerization by Blue Native PAGE
Mitochondria-enriched membrane fractions from MEFs were generated as
described above. Membrane fractions were then treated for 30 min at 30C
in the presence or absence of recombinant truncated BID (tBID) (Dewson
et al., 2008), prior to solubilization in 20 mM Bis-tris, pH 7.4, 50 mM NaCl,
10% glycerol, 2 mM DTT, and 1% digitonin. Insoluble debris was removed
by centrifugation at 13,000 3 g and 10X BN-PAGE loading dye (5% Coomas-
sie Blue G-250 [Bio-Rad] in 500 mM 6-aminohexanoic acid, 100 mM Bis-tris,
pH 7.0) was then added. Samples were electrophoresed on 4%–13% native
gels in anode buffer (50 mM Bis-tris, pH 7.0) and blue cathode buffer
(50 mM Tricine, 15 mM Bis-tris unbuffered containing 0.02% Coomassie
Blue G-250), with blue cathode buffer replaced with clear buffer (without
Coomassie Blue) when the dye front was one third through the resolving gel.
Gels were transferred to PVDF and immunoblotted for BAK (7D10) (Dewson
et al., 2008).BAK BH3 Epitope Exposure by Immunoprecipitation
Immunoprecipitation with the conformation-sensitive BH3 domain antibody
4B5 or the conformation-insensitive antibody 7D10 after solubilization in 1%
digitonin was performed as previously described (Dewson et al., 2008).
Samples were then assessed by immunoblotting for BAK.ACCESSION NUMBERS
Coordinates and structure factors have been deposited in the Protein Data
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